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ABSTRACT 
New-onset diabetes after transplantation (NODAT) is a complication following solid organ 
transplantation (SOT) and may be related to immune or inflammatory responses. We 
investigated whether single nucleotide polymorphisms (SNPs) within 158 immune- or 
inflammation-related genes contribute to NODAT in SOT recipients. The association between 
263 SNPs and NODAT were investigated in a discovery sample of SOT recipients from the 
Swiss Transplant Cohort Study (STCS, n1=696). Positive results were tested in a first STCS 
replication sample (n2=489) and SNPs remaining significant after multiple test corrections were 
tested in a second SOT replication sample (n3=156). Associations with diabetic traits were 
further tested in several large general population-based samples (n>480’000). Only SP110 
rs2114592C>T remained associated with NODAT in the STCS replication sample. Carriers of 
rs2114592-TT had 9.9 times (95%C.I.:3.22-30.5, p=0.00006) higher risk for NODAT in the 
combined STCS samples (n=1184). rs2114592C>T was further associated with NODAT in 
the second SOT sample (OR:4.8, 95%C.I.:1.55-14.6, p=0.006). On the other hand, SP110 
rs2114592C>T was not associated with diabetic traits in population-based samples, 
suggesting a specific gene-environment interaction, possibly due to the use of specific 
medications (i.e. immunosuppressants) in transplant patients and/or to the illness that may 
unmask the gene effect. 
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INTRODUCTION 
New onset diabetes mellitus after transplantation (NODAT) is a serious complication following 
solid organ transplantation (SOT)(1) affecting 2-53% of transplanted patients(2). It is 
considered that NODAT alone is associated with increased 3-year mortality and a significant 
reduction of graft survival(2). NODAT is also associated with increased cardiovascular events, 
infectious complications, and graft loss(3), which justifies the great interest in understanding 
the underlying mechanisms and risk factors contributing to the development of this disease. 
Obesity, increased age, hepatitis C (HCV) infection, family history of diabetes mellitus, African-
American or Hispanic descent are among the risk factors of NODAT(4). Immunosuppressive 
drugs such as corticosteroids and calcineurin inhibitors, in particular tacrolimus, are also 
associated with an increased risk of NODAT(1, 2). 
Both infections and NODAT are frequent complications in SOT and may be related to altered 
innate immune responses(5). The innate immune system is the first line of defence against 
infections with offending pathogens. Cytokines released from immune cells can elicit local and 
systemic inflammatory responses which can contribute to the development of type 2 diabetes 
by enhancing insulin resistance. Several proinflammatory cytokines, such as tumor necrosis 
factor alpha (TNF-α), interleukin 6 (IL-6) and interferon gamma (IFNγ), were previously shown 
to decrease the expression of insulin-sensitive glucose transporters, insulin signalling and to 
promote insulin resistance(6). Also, in the absence of infection, obesity (pre- and post-
transplant) is associated with chronic low-grade inflammation driven by adipokines derived 
from adipose tissue, which can lead to insulin resistance(7) and the development of NODAT(8). 
Genome-wide association studies (GWAS) conducted to date explain only 10% of type 2 
diabetes heritability and more diabetes susceptibility genes remain to be discovered(9). 
Regarding the genetics of NODAT, little is known and many inconsistent associations have 
been reported and are reviewed(10). Therefore, we aimed to examine whether single 
nucleotide polymorphisms (SNPs) located in different genes mainly implicated in inflammation 
or in the immune responses to infectious diseases may contribute to the development of 
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NODAT in SOT recipients. As control, analyses were extended to samples of the general 
population. 
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MATERIAL AND METHODS 
Samples description: 
The Swiss Transplant Cohort Study (STCS) (discovery and first replication samples) 
STCS is an ongoing prospective multicenter nationwide cohort project with an extensive and 
structured data collection(11, 12). Full description of this nationwide Swiss cohort (Basel, Bern, 
Geneva, Lausanne, St. Gallen and Zurich) is published elsewhere(13). Briefly, all SOT 
recipients in Switzerland are prospectively registered since May 2008. All patients with an 
allotransplant are included and are followed in their respective centers. Clinical data are 
collected at baseline, at 6, 12 months and yearly thereafter. For the discovery STCS cohort, 
patients transplanted from May 2008 to 8th of May 2011 were included in the analyses 
(n=1294). Patients from the STCS transplanted from 9th of May 2011 to May 2013 were 
included in the first replication cohort (n=759). Non Caucasian patients and patients who were 
diagnosed with glucose intolerance or diabetes before transplantation, as reported in the 
medical files, were excluded from NODAT analyses. Recipients younger than 18 years old and 
recipients with multiple organ transplantation were excluded from our study. If a patient 
received more than one transplantation during the inclusion period, only data from the first 
SOT was included in the analyses. NODAT was diagnosed if a patient needed anti-diabetic 
treatments following transplantation or if such new metabolic event was reported in the case 
report forms. For the combined STCS sample, new-onset hyperlipidemia was diagnosed if 
patients needed hypolipidemic treatment post-SOT. Patients with previous hyperlipidemia, as 
reported in the medical files, were excluded from the new-onset hyperlipidemia analyses. 
Blood samples were obtained from all SOT recipients at the time of transplantation. The study 
was approved by the corresponding ethics committee and all patients gave their written 
informed consent to participate in the study. 
Second replication SOT sample 
A full description of this cohort is published elsewhere(13-15). Briefly, a total of 200 patients 
were enrolled between 2003 and 2005 from the outpatient clinic of the Transplant Center of 
the University Hospital of Lausanne, Switzerland. Clinical data were collected retrospectively 
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from the medical files at the time of transplantation, at 1, 3, 6, 9 and 12 month post-
transplantation and yearly after until 5-year post-transplantation. Non Caucasian patients and 
patients who had glucose intolerance or diabetes before transplantation, as reported in the 
medical files, were excluded from the present study. NODAT was diagnosed if a patient 
needed anti-diabetic treatment (either insulin or oral anti-diabetic agents) following 
transplantation or fulfilled the criteria given by the WHO and ADA consensuses(16), including 
fasting blood glucose (FBG) ≥ 7.0 mmol/l in ≥ two occasions) and/or 2 hours plasma glucose 
≥ 11.1 mmol/l during oral glucose tolerance test. The study was approved by the ethics 
committee of the University of Lausanne and all patients gave their written informed consent 
to participate in the study.  
Overall, 1294, 759 and 200 patients from the STCS discovery sample, the first STCS 
replication sample and the second SOT replication sample, respectively, were included in the 
study. After excluding patients younger than 18 years of age, patients with multiple organ 
transplantation, patients with previous diabetes or prediabetes, and keeping patients with both 
clinical and genetic data available, 696, 489 and 156 patients, respectively, remained included 
in the NODAT analysis. 
Population based samples 
Significant SNPs were tested for association with diabetes development in the general 
Caucasian population (UK biobank (6’117 type 2 diabetes cases and 109’942 controls), the 
MAGIC (Meta-Analyses of Glucose and Insulin-related traits) consortium (n=46’186), and the 
DIAGRAM (DIAbetes Genetics Replication And Meta-analysis) consortium (n=69’033; 12’171 
T2D cases and 56’862 controls). Associations with obesity markers in the GIANT (Genetic 
Investigation of ANthropometric Traits) consortium (n=250’596), lipid markers in the Genome 
Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides (n>100’000) 
and with different metabolic parameters in the Cohorte Lausannoise (CoLaus, n=5338) were 
also tested. More information are given in Supplementary data. 
Polymorphisms selection: 
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287 SNPs within 158 different genes (Supplementary Table 1) implicated in the immune 
response to infectious pathogens or inflammation were selected from customized 384 Golden 
Gate Genotyping Assay (Ilumina, San Diego, California, USA). More information about 
Polymorphisms selection and genotyping are given in Supplementary data. 
Statistical analyses: 
Quantitative data are presented as median and range unless otherwise mentioned, while 
qualitative data are presented as frequency and percentage. For association studies, the chi-
square (Chi2) test or the Fisher exact test for binomial variables were used. Differences in allele 
and genotype frequencies as well as deviation from Hardy-Weinberg equilibrium (HWE) were 
assessed using chi-square test. Data were analyzed using Stata 13 (StataCorp, College 
Station TX, USA) and R version 2.13.0 software (http://www.R-project.org). 
STCS samples (discovery and first replication sample) 
NODAT in the STCS samples was analyzed using logistic regression models adjusted for 
recipient’s age at transplantation, sex, HCV status, baseline BMI, and the type of calcineurin 
inhibitor (variables identified through the univariate analysis with p-values <0.10, Table 1). 
Associations between NODAT and selected SNPs with p-values <0.01 in the STCS discovery 
sample were retained and analyzed in the STCS replication sample and in other cohorts as 
described. No correction for multiple testing was applied for the discovery sample as it was 
only used to explore associations between the selected SNPs and NODAT, and these 
associations were only considered significant if replicated in another cohort. Bonferroni 
correction for multiple testing, however, was applied for the replication cohorts. 
In the combined STCS sample, logistic regression models adjusted for recipient’s age at 
transplantation, sex, and baseline BMI were used to analyze other metabolic parameters 
including new-onset hyperlipidemia after transplantation. Due to nonlinearity of BMI and HDL-
cholesterol models and the absence of any linear transformation, the association between the 
SNPs with BMI and HDL-cholesterol levels was assessed by fitting a Generalized Additive 
Mixed Model (GAMM) to allow a smooth trend for the response in time based on multiple 
observations for each patient (using a thin plate regression spline basis) adjusting for 
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recipient’s age at transplantation, sex and baseline BMI (also adjusted for the use of 
hypolipidemic drugs for analysis of HDL-cholesterol). GAMMs were fitted using the mgcv 
package of R (settings were fixed at package defaults). In order to be more conservative, the 
uncertainty of estimated parameters was assessed by 1000 bootstraps at the subject level. 
Linear mixed models were used for total blood cholesterol and LDL-cholesterol analyses. 
These models were adjusted for recipient’s age at transplantation, sex, baseline BMI, and 
hypolipidemic drugs intake.  
Second replication SOT sample 
Logistic regression models were applied for NODAT analyses adjusted for recipient’s age at 
transplantation, sex, baseline BMI and type of calcineurin inhibitors.  
Population-based samples 
SNPs significantly associated with different metabolic traits in SOT samples were analyzed in 
population-based samples.  Multivariate linear regression with allele dosage in which potential 
confounding factors such as age, sex, batch effect, five ancestry principal components and 
smoking status were used. FBG, oral glucose tolerance test, the surrogate estimates of beta-
cell function (HOMA-B) and insulin resistance (HOMA-IR) were analyzed in the MAGIC study, 
while FBG was investigated in the CoLaus study. 
BMI, waist circumference and waist-to hip ratio were the only adiposity traits analyzed by the 
GIANT Consortium. Triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol were 
analyzed in the “Genome Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and 
triglycerides” study(17). 
Estimation of the functional activity of the significant SNPs: 
The RegulomeDB(18) database was used to estimate the functional activity of the significant 
SNPs. This database annotates SNPs with known and predicted regulatory elements in the 
intergenic regions of the Homo sapiens genome and reveals known and predicted regulatory 
DNA elements including regions of DNase hypersensitivity, binding sites of transcription 
factors, and promoter regions that have been biochemically characterized to regulate 
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transcription. Source of these data include public datasets from GEO, the ENCODE project, 
and the published literature. 
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RESULTS 
General characteristics of the study populations 
The incidence of NODAT in the discovery sample was 21.8%. NODAT patients were older with 
higher baseline BMI and were more often prescribed then tacrolimus-based maintenance 
immunosuppression compared to non-NODAT patients. A detailed description of this sample 
is presented in Table 1. Similar descriptions for the replication samples are presented in 
Supplementary Tables 2 and 3. 
Polymorphisms in immune related genes and NODAT in the STCS and the replication 
samples 
The minor allele frequency (MAF) was <5% for 12 SNPs in our discovery sample and they 
were removed from the analyses. Additionally, 12 SNPs did not meet HWE (p<0.05), therefore, 
a total of 263 SNPs were finally analyzed (Supplementary Table 1, Part. A,B,C). Among these 
SNPs, 10 polymorphisms were associated with NODAT (p-value<0.01 in additive models 
and/or allele dosage; Supplementary Table 4). These SNPs were used for replication in the 
first replication sample (second subset of the STCS sample). 
Among these 10 SNPs only one SNP, the SP110 nuclear body protein (SP110) 
rs2114592C>T, was associated with NODAT in the first replication sample after correction for 
multiple testing (Table 2) and was therefore investigated in the second SOT replication sample 
and in other population based samples. A significant observation was also noticed when 
combining both STCS samples, with SP110 rs2114592-TT genotype carriers having 9.9 
(95%C.I.: 3.22-30.5, p=0.00006) higher risk of developing NODAT compared to reference 
genotype carriers (Table 2). Importantly, SP110 rs2114592C>T SNP was also associated with 
NODAT in the second SOT replication sample (n=156, OR:4.8, 95%C.I.:1.55-14.6, p=0.006). 
Time to NODAT in the combined STCS sample by SP110 genotype is shown in Figure 1, with 
an increased incidence of NODAT during the first year in SP110 rs2114592-TT genotype 
carriers (p=0.003) compared to other genotypes. 
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A second SNP (rs2907749A>G) within the nucleotide-binding oligomerization domain 
containing 1 (NOD1) was associated with NODAT in the discovery and in the first replication 
samples, but this association did not remain significant after multiple testing correction 
(Supplementary Table 5a). This SNP was not significantly associated with NODAT in the 
second SOT replication sample (data not shown), but was significantly associated with NODAT 
(n=1156), new-onset hyperlipidemia (n=1051), lower HDL-cholesterol (n=1051), and higher 
total cholesterol levels (n=1051) in the combined STCS sample (Supplementary Table 5a and 
5b). 
SP110 rs2114592C>T SNP and other metabolic syndrome complications in the 
combined STCS sample 
The associations between SP110 rs2114592C>T SNP and other metabolic syndrome 
complications were investigated in the combined STCS sample (n=1071). No association was 
observed between SP110 rs2114592C>T SNP and BMI (dichotomized into normal versus 
overweight or obese) at 12 months post-SOT or when analyzing the evolution of BMI over time 
between different genotype groups (data not shown). Carriers of SP110 rs2114592-TT 
genotype presented 3 times higher risk of developing new-onset hyperlipidemia after 
transplantation (OR:3.41, 95%C.I.:1.06-11.0, p=0.04) when compared to the reference 
genotype (SP110 rs2114592-CC), but this genotype was not associated with differences of 
lipid blood levels (Supplementary Table 6). 
SP110 rs2114592C>T SNP and metabolic markers in population-based samples 
In the population-based samples, SP110 rs2114592C>T SNP was not associated with the 
different metabolic markers investigated, including available diabetes markers (Supplementary 
Table 7).  
Tagging SNPs of SP110 gene: 
Twenty-six tagging SNPs within the SP110 gene were found using HapMap Genome Browser 
(Supplementary Table 8). Only SP110 rs7580900T>C SNP was associated with NODAT in the 
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discovery sample (n=695, OR:0.72, 95%C.I.:0.55-0.95, p=0.02 in additive model and 
OR=0.43, 95%C.I.:0.23-0.80, p=0.007 for rs7580900-CC genotype compared to the reference 
genotype). This significant association between SP110 rs7580900T>C SNP and NODAT was 
not replicated in the different replication samples (data not shown).  
Estimation of the functional activity of SP110 rs2114592C>T SNP 
The functional activity of SP110 rs2114592C>T SNP was investigated using the RegulomeDB 
database(18). We found 22 SNPs to be in complete linkage disequilibrium (r2=1) with SP110 
rs2114592C>T SNP (intronic variant), among them the SP110 rs75411703 SNP which shows 
a deoxyribonuclease sensitivity quantitative trait loci (dsQTL) effect and is linked to the 
expression of the target gene(19). Additionally, by using the eQTL gene browser-gene network 
database(20), SP110 rs2114592-T allele is associated with a decrease of SP110 expression 
in the blood (p-value=3.87E-26). Altogether, these data suggest that SP110 rs2114592C>T 
SNP might have important regulatory functions. 
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DISCUSSION: 
Inflammation is intimately linked with the development of diabetes in the general population 
(reviewed in(21, 22)) and recipients of SOT(5). In our study ten polymorphisms within 10 
different genes primarily implicated in the innate immune response or inflammation were 
significantly (p<0.01) associated with NODAT in a discovery cohort of 696 patients from the 
STCS without a previous history of diabetes or glucose intolerance before SOT. These 
significant results were tested for replication in 2 samples with SOT (a second subset of the 
STCS and a third independent sample with SOT) and only one polymorphism in the intronic 
region of SP110 gene (rs2114592C>T) was found to be significantly associated with NODAT 
in both replication samples. Carriers of the rs2114592-TT genotype had nearly 10 times 
increased risk of NODAT in the combined STCS sample. They also showed an increased risk 
of new-onset hyperlipidemia. However, SP110 rs2114592C>T was not associated with 
diabetes in large population-based samples. 
SP110 nuclear body protein (encoded by the SP110 gene) is an activator of gene transcription 
and may serve as a nuclear hormone receptor coactivator(23). This gene is a member of the 
SP100/SP140 family of nuclear body proteins and is involved in several cellular processes 
such as apoptosis, cell cycle control, and a prototype type I interferon-induced gene that 
regulates immune responses in particular in myeloid cells differentiation. Most of the studies 
investigating SP110 have shown its role in immunoprotective defenses against infectious 
organisms in humans, mainly tuberculosis(24). Human SP110 is the closest homolog of mouse 
intracellular pathogen resistance-1 (Ipr1) protein, and previous animal studies showed that the 
expression of the Ipr1 transgene in macrophages limits the multiplication of M. tuberculosis 
and switches the infected macrophages towards an apoptotic cell death pathway(24). Several 
studies in human investigated the association between polymorphisms of SP110 (among them 
the rs2114592C>T) and the risk of developing pulmonary tuberculosis, but results were 
inconsistent(25, 26). No previous studies related SP110 or its polymorphisms to diabetes or 
NODAT. Interestingly, SP110, as a transcriptional coactivator, enhances transcription of genes 
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with retinoic acid response elements(23) and several of these genes such as IL2RA, PEPCK1, 
UCP1 and CD38(27) are known candidate genes for type 1 and type 2 diabetes. Retinoids are 
important in glucose and lipid metabolism and the activation of the retinoic acid cascade 
through the retinoic acid response elements has been previously related to the development 
of diabetes, adipogenesis and insulin resistance (reviewed in(28)). Functional activity of SP110 
rs2114592C>T was investigated and was linked to the expression of the target gene. 
Moreover, it has several histone marks and influences the binding of several proteins, among 
them some important immune regulatory proteins (e.g.: IRF-4 and NF-ATc1), but also the 
transcription factor E2-alpha (encoded by TCF3). TCF3 is a transcriptional regulator that binds 
to IEB1 and IEB2 which are short DNA sequences in the insulin gene transcription control 
region providing a new possible mechanism relating SP110 to the development of diabetes 
and/or NODAT. 
Homozygous loss of function mutations in SP110 in humans cause Hepatic Veno-occlusive 
Disease with Immunodeficiency (VODI), a monogenic autosomal recessive primary 
immunodeficiency associated with hepatic vascular occlusion and fibrosis(29) and a severe 
combined immunodeficiency despite normal lymphocyte numbers. VODI is associated with 
high mortality either due to hepatic failure but also to life threatening infections, often 
pneumocystis(29). SP110 deficient B cells have reduced ability to respond to T cell dependent 
signals and to differentiate into plasmablasts which might be the explanation for the observed 
hypogammaglobulinemia in VODI(30). Metabolic alterations, especially diabetes, are not 
hallmarks of VODI; however, these patients often die within the first 12 months of life, so long 
long-term metabolic complications of SP110 deficiency might be missed(29). These data 
altogether suggest that SNPs within the SP110 gene may be linked in populations at risk with 
an altered inflammatory response, leading to the development of NODAT. 
We also tested whether the associations between SP110 rs2114592C>T SNP and diabetes 
are present in the general population. No effect was observed in two large population-based 
samples and a large case-control sample of patients with type 2 diabetes, pointing out the 
implication of this SNP only in populations at high risk of developing metabolic diseases 
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including diabetes. Although there is a strong correlation between inflammation and Type 2 
diabetes in the general population, our results suggest a specific gene-environment interaction, 
possibly due to the use of specific medications (i.e. immunosuppressants) in transplant 
patients and/or to the illness that may unmask the gene effect.
This study has several limitations and strengths. One of the major limitations of genetic studies 
in this field is the different definitions used for NODAT. However, it should be noted that 
NODAT definition in the discovery and second STCS replication samples was the same and 
the closest to the criteria given by the WHO and ADA consensuses (16), which is a strength in 
our study. Even though the association between SP110 rs2114592C>T and NODAT were 
replicated in two cohorts, they are modest in size and not truly independent. The present 
finding must therefore be confirmed by future studies. The selection of the SNPs was based 
on SNPs already associated with infections and inflammation in the literature and does not 
cover all variants within these genes, so unknown variants within these candidate genes with 
important associations with NODAT or novel pro-inflammatory variants may have been 
missed. Our findings on Caucasian samples cannot be extrapolated to other ethnicities. The 
present results do not allow determining whether SP110 rs2114592C>T SNP is the causative 
variant or merely a proxy of one or more yet unidentified variants. Despite the important 
regulatory functions suggested by the RegulomeDB and the eQTL databases, further studies 
are needed to elucidate which precise mechanisms underlie the observed associations. 
Another limitation is the low allelic frequency of SP110 rs2114592C>T with only few 
homozygote carriers of TT genotype being observed (see supplementary Table 9). Thus 
SP110 rs2114592C>T contributes only to a small fraction of new onset diabetes in the 
analyzed populations. On the other hand, the fact that these results were replicated in two 
independent samples with SOT strengthens the validity of our data.  In addition, the high 
observed ORs suggest important clinical implications of SP110 rs2114592C>T SNP. Well-
designed prospective clinical trials should therefore be conducted to test whether genetic 
testing before transplantation may offer more precise new onset diabetes risk stratification. In 
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addition, SP110 may be even more relevant in predicting diabetes in specific subgroups of at-
risk SOT patients (e.g. HCV-infected transplant recipients, or overweight patients), but this 
remains to be analyzed.  
In conclusion, our results link for the first time the SP110 gene in the development of diabetes 
and other metabolic complications in SOT recipients. While the pathway by which the SP110 
rs2114592C>T SNP is associated with diabetes remain unraveled, our study opens the door 
for further investigation of this SNP and provides a promising new candidate gene for diabetes 
development. Ultimately, an important question will be to determine whether personalized 
strategies based on genetic testing in pre-transplant patients may help to reduce the risk of 
developing diabetes. 
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Figure 1. Time to new onset diabetes after transplantation (NODAT) in the combined Swiss Transplant Cohort 
Study (STCS) sample by SP110 genotype for the rs2114592 polymorphism. 
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Time since transplantation in months (numbers at risk) 
SP110 rs2114592 = CC SP110 rs2114592 = CT 
SP110 rs2114592 = TT
Time to NODAT in the combined STCS sample
6 (1235) 12 (1193) 24 (897) 36 (414) 48 (31)
Table 1: Clinical characteristics of the solid organ transplantation discovery sample (Swiss transplant cohort study 
first sample). 
Characteristic Total Non-NODAT NODAT p-value 
Sample size (%) 696 544 (78.2) 152 (21.8) 
Age at transplantation (years), median (range) 52 (18-79) 51 (18-79) 56 (19-73)  0.0003 
Recipient sex (Male) [%] 65.6 63.7 72.4 0.05 
Living donor [%] 32.7 33.7 29.0 0.27 
Donor age (years) median (range) 52 (1-86) 52 (1-85) 54 (14-86) 0.73 
Donor sex (Male) [%] 53.3 54.8 48.0 0.14 
Recipients anti-HCV [% of HCV positive] 7.7 6.5 11.8 0.03 
Organ [%] 
 Kidney 
 Liver  
 Lung 
 Heart 
69.1 
15.5 
9.2 
6.2 
70.6 
15.1 
9.2 
5.1 
63.8 
17.1 
9.2 
9.9 
0.15 
Body mass index (kg/m2), median (range) 
 Pre-transplant 24.4 (13.7-41.2) 24.2 (13.7-39.1) 25.8 (15.2-41.2) 0.0001 
      One year follow-up 25.1 (15.4-44.4) 24.7 (15.4-44.4) 26.6 (17.3-44.3) 0.0005 
Calcineurin inhibitors, [%] 0.004 
  Tacrolimus 66.5 64.1 75.0 
 Cyclosporine 26.2 29.1 15.8 
 None 7.3 6.8 9.2 
NODAT: New-onset diabetes after transplantation, HCV: hepatitis C.
Table 2: Association between SP110 rs2114592 C>T genotypes and new-onset diabetes after transplantation in the 
Swiss transplant cohort study (STCS) replication sample and the combined sample. 
CC CT TT T allele dosage 
STCS replication sample 
Sample size 376 105 8 
Odds ratio (95% CI) 1 (Ref.) 1.26 (0.72 - 2.20) 8.90 (1.97 - 40.0) 1.70 (1.08 - 2.66) 
P-corrected value* 1.0 0.04 0.20 
Combined STCS samples 
Sample size 935 234 15 
Odds ratio (95% CI) 1 (Ref.) 1.16 (0.81 - 1.65) 9.90 (3.22 - 30.5) 1.53 (1.13 - 2.06) 
P-value 0.42 0.00006 0.005 
Results are expressed as odds ratio and (95% confidence interval). Statistical analysis by logistic regression 
adjusting for age of recipient at transplantation (continuous variable), sex of the recipient, baseline BMI 
(continuous variable), type of calcineurin inhibitor (no calcineurin inhibitor / tacrolimus / cyclosporine). No 
adjustement was done for HCV status (as in the discovery sample) because data were not available. 
*P- values were corrected using Bonferroni correction for multiple testing (corrected P-value = original p-value *
10)
SUPPLEMENTARY INFORMATIONS 
Population based samples description: 
The Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) 
MAGIC is a large-scale meta-analysis of genome-wide data for continuous diabetes-related 
traits in participants without diabetes(1). Meta-analyses of ~2.5 million directly genotyped or 
imputed autosomal single nucleotide polymorphisms (SNPs) were performed from genome-wide 
association studies (GWAS). These cohorts include up to 46’186 non-diabetic participants of 
European descent informative for FBG, the surrogate estimates of beta-cell function (HOMA-B) 
and insulin resistance (HOMA-IR) derived from fasting variables by homeostasis model 
assessment and up to 15’234 non-diabetic individuals informative for 2 hour oral glucose 
tolerance test(2). 
The UK biobank for diabetes 
UK Biobank recruited 500,000 participants aged between 40-69 years in 2006-2010 from across 
the country to take part in this project. They have undergone measures, provided blood, urine 
and saliva samples for future analysis, detailed information about themselves and agreed to 
have their health followed. The UK biobank has type 2 diabetes status (diagnosed by the 
doctors) in 116,059 individuals of white British ancestry. 
The DIAGRAM (DIAbetes Genetics Replication And Meta-analysis) consortium 
The DIAGRAM consortium is a meta-analysis of GWAS data in 12’171 type 2 diabetes cases 
vs. 56’862 controls in individuals of European ancestry(3). 
Genetic Investigation of ANtropometric Traits (GIANT) consortium 
The GIANT consortium performed a meta-analysis of GWAS data with a discovery set of 
123’865 individuals of European ancestry from 46 studies for height, BMI and waist-to hip 
ratio(4, 5). 
 
 
Genome Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides 
Data on lipid traits have been downloaded from “Genome Wide Associations Scans for Total 
Cholesterol, HDL-C, LDL-C and triglycerides” website which is a meta-analysis of 46 lipid 
GWASs. These studies together comprise >100,000 individuals of European descent (maximum 
sample size 100,184 for Total Cholesterol, 95,454 for LDL-C, 99,900 for HDL-C and 96,598 for 
triglycerides), ascertained in the United States, Europe or Australia(6, 7). 
Cohorte Lausannoise (CoLaus) 
Participants aged 35 to 75 years in this population-based study (CoLaus) were recruited 
between June 2003 and May 2006 as previously described(8). The assessment included 
cardiovascular risk factors such as the BMI, fat mass, waist circumference, blood pressure, 
blood glucose, triglycerides and HDL-C. In addition, all Caucasians (91% of the sample) 
underwent a genetic exam (n=5338). Of note, CoLaus is part of the MAGIC and GIANT studies. 
Polymorphism selection and genotyping: 
The SNPs from genes previously associated with infectious phenotypes or inflammation were 
selected based on the literature search using Medline database until June 2012. SNPs from 
genes that were not studied so far were selected based on tagging SNP approach. 
Genomic DNA was extracted from blood specimens using the Gentra Puregene Blood Kit 
(Qiagen). Genotyping was performed using a customized GoldenGate Genotyping Assay on 
Veracode platform (Illumina, San Diego, California), unless otherwise indicated. Results were 
analyzed on a BeadXpress Reader according to standard protocols and quality controls. 
Additional SNPs in the discovery sample and all the SNPs from the first replication sample were 
genotyped using the Competitive Allele-Specific PCR system (KASP™ technology, LGC 
Genomics, UK) on QuantStudio™ 12K Flex system or ABI 7500 Fast real-time thermocycler 
(Applied Biosystems) according to the manufacturer’s protocol. The KASP primers were 
designed by Kraken™ assay design and workflow management software and further validated 
by the manufacturer (LGC Genomics, UK).  
Genotypes of the second replication were exported from the Illumina 200K cardiometabochip(9). 
The CardioMetabochip is a custom Illumina iSelect genotyping array designed to test DNA 
variation of 200’000 SNPs from regions identified by large scale meta-analyses of GWAS for 
metabolic and cardiovascular traits. Customized SNPs were added to the CardioMetabochip 
which included the SNP significantly associated with NODAT in the STCS cohorts. 
CardioMetabochip genotyping was performed at the iGE3 genomics platform of the University of 
Geneva (10). Genotyping for the CoLaus subjects was performed using the Affymetrix 
GeneChipR Human Mapping 500K array set. 
Supplementary table 1 (Part A): Selected genetic polymorphisms, allelic variants and chromosomal positions 
rs_number Alleles Position Gene Chromosome 
rs1033638 C/T 11026660 MASP2 1 
rs1061622 G/T 12192898 TNFRSF1B 1 
rs631090 C/T 22659910 C1QB 1 
rs7530511 C/T 67219704 IL23R 1 
rs2476601 A/G 113834946 PTPN22 1 
rs1016140 G/T 116533925 CD58 1 
rs1205 C/T 159712443 CRP 1 
rs1801274 C/T 161509955 FCGR2A 1 
rs10800098 A/G 165439858 RXRG 1 
rs3024493 G/T 206770623 IL10 1 
rs1800871 C/T 206773289 IL10 1 
rs1800896 A/G 206773552 IL10 1 
rs1800890 A/T 206776020 IL10 1 
rs1518108 C/T 206869829 IL20 1 
rs3813946 A/G 207454348 CR2 1 
rs1048971 A/G 207472977 CR2 1 
rs17615 A/G 207473117 CR2 1 
rs6656401 A/G 207518704 CR1 1 
rs851193 A/G 223121509 TLR5 1 
rs5744105 C/G 223142735 TLR5 1 
rs3806265 C/T 247423034 NLRP3 1 
rs4612666 C/T 247435768 NLRP3 1 
rs10754558 C/G 247448734 NLRP3 1 
rs212706 C/T 32226063 NLRC4 2 
rs408813 G/T 32251321 NLRC4 2 
rs385076 C/T 32264782 NLRC4 2 
rs2272127 C/G 102423413 IL18RAP 2 
rs917997 A/G 102454108 IL18RAP 2 
rs1800587 C/T 112785383 IL1A 2 
rs1143634 C/T 112832813 IL1B 2 
rs1143633 A/G 112832890 IL1B 2 
rs1143627 C/T 112836810 IL1B 2 
rs4251961 C/T 113116890 IL1RN 2 
rs419598 C/T 113129630 IL1RN 2 
rs3806496 C/T 118940998 MARCO 2 
rs1318645 C/G 118942009 MARCO 2 
rs6761637 C/T 118981487 MARCO 2 
rs13432 C/G 159769216 CD302 2 
rs1921310 A/G 161192690 TANK 2 
rs1990760 C/T 162267541 IFIH1 2 
rs2280235 C/T 190979104 STAT1 2 
rs1547550 C/G 190980999 STAT1 2 
rs2280233 A/G 190985840 STAT1 2 
rs2066802 C/T 191009941 STAT1 2 
rs231775 A/G 203867991 CTLA4 2 
rs3087243 A/G 203874196 CTLA4 2 
rs2276631 A/G 218384290 SLC11A1 2 
rs17221959 C/T 218387907 SLC11A1 2 
rs1059823 A/G 218395121 SLC11A1 2 
rs2114592 C/T 230210491 SP110 2 
rs11556887 C/T 230212961 SP110 2 
rs35060588 C/G 10213318 IRAK2 3 
rs3844283 C/G 10222796 IRAK2 3 
rs708035 A/T 10234479 IRAK2 3 
rs1801282 C/G 12351626 PPARG 3 
rs6853 A/G 38142879 MYD88 3 
rs3732378 A/G 39265671 CX3CR1 3 
rs3732379 C/T 39265765 CX3CR1 3 
rs1799864 A/G 46357717 CCR2 3 
rs1799987 A/G 46370444 CCR5 3 
rs414171 A/T 50612068 CISH 3 
rs352139 A/G 52224356 TLR9 3 
rs600718 A/T 101851531 NFKBIZ 3 
rs1129055 A/G 122119472 CD86 3 
rs1840680 A/G 157438240 PTX3 3 
rs11096955 A/C 38774486 TLR10 4 
rs11096956 G/T 38774559 TLR10 4 
rs5743618 G/T 38797027 TLR1 4 
rs4833095 C/T 38798089 TLR1 4 
rs5743611 C/G 38798593 TLR1 4 
rs5743818 G/T 38827542 TLR6 4 
rs5743810 C/T 38828729 TLR6 4 
rs2227306 C/T 73741338 IL8 4 
rs1554013 C/T 76012331 CXCL10 4 
rs1585215 A/G 102523317 NFKB1 4 
rs1585213 A/G 102523541 NFKB1 4 
rs230547 C/T 102615104 NFKB1 4 
rs2069762 G/T 122456825 IL2 4 
rs4833837 A/G 122615808 IL21 4 
rs4696480 A/T 153685974 TLR2 4 
rs3804099 C/T 153703504 TLR2 4 
rs3804100 C/T 153704257 TLR2 4 
rs5743303 A/T 186067699 TLR3 4 
rs5743305 A/T 186068179 TLR3 4 
rs3775291 A/G 186082920 TLR3 4 
rs1494555 C/T 35871088 IL7R 5 
rs10512747 C/T 40841639 CARD6 5 
rs17473484 C/T 115579763 TICAM2 5 
rs2288384 C/T 115580331 TICAM2 5 
rs256996 A/G 115580393 TICAM2 5 
rs2070721 A/C 132490150 IRF1 5 
rs2549009 A/G 132491073 IRF1 5 
rs1295686 A/G 132660151 IL13 5 
rs2070874 C/T 132674018 IL4 5 
rs7380824 C/T 139477397 TMEM173 5 
rs1131769 A/G 139478334 TMEM173 5 
rs2569190 A/G 140633331 CD14 5 
rs5744455 C/T 140633722 CD14 5 
rs3212227 A/C 159315942 IL12B 5 
rs2853696 A/G 159317652 IL12B 5 
rs6887695 C/G 159395637 IL12B 5 
rs12211228 C/G 408833 IRF4 6 
rs9391981 C/G 3086772 RIPK1 6 
rs1048412 A/G 30064718 ZNRD1 6 
rs2071592 A/T 31547563 NFKBIL1 6 
rs1800629 A/G 31575254 TNF 6 
rs3093662 A/G 31576412 TNF 6 
rs7453920 A/G 32762235 HLADQB2 6 
rs2228396 A/G 32830032 TAP2 6 
rs1057141 A/G 32850997 TAP1 6 
rs3077 C/T 33065245 HLADPA1 6 
rs9277535 A/G 33087084 HLADPB1 6 
rs529948 A/G 44268632 NFKBIE 6 
rs1974226 A/G 52190537 IL17A 6 
rs2397084 C/T 52237046 IL17F 6 
rs1800795 C/G 22727026 IL6 7 
rs2907748 C/T 30433407 NOD1 7 
rs2907749 A/G 30446125 NOD1 7 
rs2075818 C/G 30456766 NOD1 7 
rs1334512 G/T 80638588 CD36 7 
rs4728142 A/G 128933913 IRF5 7 
rs1800972 C/G 6877901 DEFB1 8 
rs42490 A/G 89766285 RIPK2 8 
rs40457 A/G 89811459 RIPK2 8 
rs9695310 C/G 32464137 DDX58 9 
rs10813831 A/G 32526148 DDX58 9 
rs10982385 G/T 114730737 TNFSF15 9 
rs4574921 C/T 114776054 TNFSF15 9 
rs3810936 C/T 114790605 TNFSF15 9 
rs6478108 C/T 114796423 TNFSF15 9 
rs2737190 A/G 117701903 TLR4 9 
rs10759932 C/T 117702866 TLR4 9 
rs11536889 C/G 117715853 TLR4 9 
rs10818488 A/G 120942809 TRAF1 9 
rs2900180 C/T 120944104 TRAF1 9 
rs2300929 C/T 120954562 C5 9 
rs2269066 C/T 120974740 C5 9 
rs17611 A/G 121006922 C5 9 
rs17514136 A/G 134880818 FCN2 9 
rs1801157 A/G 44372809 CXCL12 10 
rs1800450 A/G 52771475 MBL2 10 
rs7095891 A/G 52771701 MBL2 10 
rs7096206 C/G 52771925 MBL2 10 
rs11003125 C/G 52772254 MBL2 10 
rs5744034 C/T 1275007 TOLLIP 11 
rs4963060 A/G 1299830 TOLLIP 11 
rs7937602 A/C 35170144 CD44 11 
rs5030419 C/G 36509193 TRAF6 11 
rs2227973 A/G 36575763 RAG1 11 
rs4151040 C/T 36577519 RAG1 11 
rs1056403 C/T 36579620 RAG1 11 
rs501192 A/G 105029658 CASP1 11 
rs1946518 G/T 112164735 IL18 11 
rs2228055 A/G 117994131 IL10RA 11 
rs2229114 C/T 117999163 IL10RA 11 
rs8177352 A/G 126283948 TIRAP 11 
rs611953 A/G 126293796 TIRAP 11 
rs740839 C/T 6229471 CD9 12 
rs4149570 G/T 6342424 TNFRSF1A 12 
rs2024301 A/T 8125585 CLEC4A 12 
rs1133104 G/T 8138526 CLEC4A 12 
rs4296104 A/G 8454092 CLEC6A 12 
rs10841845 A/G 8533837 CLEC4E 12 
rs11046143 A/G 8542421 CLEC4E 12 
rs526680 C/T 9916703 CLEC2A 12 
rs580960 C/T 9930538 CLEC2A 12 
rs479499 A/C 9984958 CLEC12A 12 
rs581949 C/T 9996807 CLEC1B 12 
rs11053560 C/T 10029855 CLEC9A 12 
rs7315231 A/G 10054326 CLEC9A 12 
rs16910526 G/T 10118488 CLEC7A 12 
rs7959064 A/G 10131559 CLEC7A 12 
rs2617160 A/T 10392998 KLRC4 12 
rs4251520 C/T 43781535 IRAK4 12 
rs11465955 C/T 66209619 IRAK3 12 
rs1370128 C/T 66224858 IRAK3 12 
rs2069707 C/G 68160508 IFNG 12 
rs2069705 C/T 68161231 IFNG 12 
rs741344 A/G 68203306 IL26 12 
rs2227485 C/T 68253933 IL22 12 
rs11106877 A/G 77827755 NAV3 12 
rs4761403 A/G 77843176 NAV3 12 
rs1131454 C/T 112911065 OAS1 12 
rs10774671 A/G 112919388 OAS1 12 
rs2072136 C/T 112961114 OAS3 12 
rs2010604 C/G 112970403 OAS3 12 
rs2072138 C/G 112987088 OAS2 12 
rs2072137 A/G 113003116 OAS2 12 
rs2240185 C/G 113006312 OAS2 12 
rs1169279 A/G 121018070 OASL 12 
rs2393799 C/T 121132209 P2RX7 12 
rs1718119 C/T 121177300 P2RX7 12 
rs3751143 G/T 121184501 P2RX7 12 
rs3764147 A/G 43883789 C13orf31 13 
rs10507522 A/G 43904864 CR13ORF31 13 
rs2582869 A/G 108259797 TNFSF13B 13 
rs8904 C/T 35402011 NFKBIA 14 
rs3138053 A/G 35405648 NFKBIA 14 
rs6572335 A/G 45965382   14 
rs1131877 A/G 102875712 TRAF3 14 
rs4774 C/G 10906991 CIITA 16 
rs2903692 A/G 11144926 CLEC16A 16 
rs6498169 A/G 11155472 CLEC16A 16 
rs11074956 G/T 11243864 CLEC16A 16 
rs1805015 C/T 27362859 IL4R 16 
rs4243232 C/T 30503402 ITGAL 16 
rs2230433 C/G 30506720 ITGAL 16 
rs9302752 C/T 50685192 NOD2 16 
rs7194886 C/T 50691282 NOD2 16 
rs2066843 C/T 50711288 NOD2 16 
rs5743289 C/T 50722863 NOD2 16 
rs5743291 A/G 50723365 NOD2 16 
rs1024611 C/T 34252769 CCL2 17 
rs4586 C/T 34256250 CCL2 17 
rs1133763 A/C 34320812 CCL8 17 
rs2280789 C/T 35879999 CCL5 17 
rs2107538 C/T 35880776 CCL5 17 
rs2227319 A/G 40014592 CSF3 17 
rs2293152 C/G 42329511 STAT3 17 
rs9891119 A/C 42355962 STAT3 17 
rs4794067 C/T 47731462 TBX21 17 
rs17244587 A/G 47745669 TBX21 17 
rs2287886 A/G 7747650 CD209 19 
rs4804803 A/G 7747847 CD209 19 
rs735240 A/G 7748450 CD209 19 
rs2277998 A/G 7766742 CLEC4M 19 
rs5498 A/G 10285007 ICAM1 19 
rs11575934 A/G 18075808 IL12RB1 19 
rs436857 A/G 18086825 IL12RB1 19 
rs12980275 A/G 39241143 IL28B 19 
rs8099917 G/T 39252525 IL28AB 19 
rs10418239 C/G 48219568 CARD8 19 
rs2288877 A/G 48234294 CARD8 19 
rs2043211 A/T 48234449 CARD8 19 
rs2304204 A/G 49665763 IRF3 19 
rs1043680 C/G 55000979 NLRP2 19 
rs299170 C/T 55805104 NLRP11 19 
rs1363758 A/C 55818381 NLRP11 19 
rs379327 A/G 55858800 NLRP4 19 
rs306487 A/G 55971826 NLRP8 19 
rs8116776 C/T 3858160 MAVS 20 
rs7262903 A/G 3862380 MAVS 20 
rs2232571 C/T 38345681 LBP 20 
rs2232582 C/T 38350862 LBP 20 
rs1883832 C/T 46118343 CD40 20 
rs3765459 A/G 46128768 CD40 20 
rs7341 G/T 58994761 CTSZ 20 
rs236729 C/T 59004920 CTSZ 20 
rs3208008 A/C 63694757 TNFRSF6B 20 
rs2834167 A/G 33268483 IL10RB 21 
rs1012335 C/G 33341701 IFNAR1 21 
rs2284553 A/G 33404389 IFNGR2 21 
rs2268241 A/G 33408744 IFNGR2 21 
rs879574 A/T 17107415 IL17RA 22 
rs879577 A/G 17108319 IL17RA 22 
rs755622 C/G 23894205 MIF 22 
rs4821544 C/T 36862461 NCF4 22 
rs729749 C/T 36867804 NCF4 22 
rs864058 C/T 12887911 TLR7 X 
rs3764880 A/G 12906707 TLR8 X 
rs1548731 C/T 12909828 TLR8 X 
rs5744080 C/T 12919685 TLR8 X 
rs7061789 A/G 154015024 IRAK1 X 
 
Supplementary table 1 (Part B): Excluded genetic polymorphisms (not meeting Hardy-Weinberg equilibrium with 
p<0.05), allelic variants and chromosomal positions 
rs_number Alleles Position Gene Chromosome 
rs12033074 C/G 22640116 C1Q 1 
rs35829419 A/C 247425556 NLRP3 1 
rs2239704 G/T 31572364 LTA 6 
rs10870077 C/G 136369439 CARD9 9 
rs266093 C/G 44370760 CXCL12 10 
rs5030737 C/T 52771482 MBL2 10 
rs353644 A/G 35160066 CD44 11 
rs12813085 C/T 68224048 IL26 12 
rs3087456 A/G 10877045 CIITA 16 
rs1634517 A/C 36105010 CCL4 17 
rs6503695 C/T 42347515 STAT3 17 
rs882643 C/G 17110933 IL17RA 22 
Supplementary table 1 (Part C): Excluded genetic polymorphisms (minor allele frequency <5%), allelic variants and 
chromosomal positions  
rs_number Alleles Position Gene Chromosome 
rs72550870 AG 11046609 MASP2 1 
rs5743708 AG 153705165 TLR2 4 
rs763780 CT 52236941 IL17F 6 
rs4986790 AG 117713024 TLR4 9 
rs4986791 CT 117713324 TLR4 9 
rs1800451 AG 52771466 MBL2 10 
rs5743856 AG 1308608 TOLLIP 11 
rs2066807 CG 56346898 STAT2 12 
rs2066844 CT 50712015 NOD2 16 
rs2066845 CG 50722629 NOD2 16 
rs2302267 GT 12867459 TLR7 X 
rs5744043 CT 12906628 TLR8 X 
Supplementary table 2: Clinical characteristics of the solid organ transplantation first replication sample (Swiss 
transplant cohort study second sample)  
 
Characteristic Total Non-NODAT NODAT p-value 
Sample size 489 398 91  
Age at transplantation (years), median (range) 51 
(18 – 75) 
50 
(18 – 75) 
54.5 
(20 – 72) 
0.03 
Recipient sex (Males) [%] 64.0 63.9 64.4 0.92 
Living donor [%] 26.5 27.8 21.1 0.19 
Donor sex (Males) [%] 52.9 52.0 56.7 0.42 
Recipients anti-HCV [%] 8.3 8.1 8.9 0.81 
Organ, [%]    0.28 
Kidney 56.5 54.8 63.7  
Liver 19.6 21.1 13.1  
Lung 15.5 15.6 15.4  
Heart 8.4 8.5 7.8  
Body mass index (kg/m2), median (range)     
Pre-transplant 24.6 
(13.4 – 43.5) 
24.5 
(13.4 – 43.5) 
25.5 
(16.3 – 41.0) 
0.21 
One year follow-up 24.8 
(13.7 – 41.7) 
24.7 
(14.9 – 41.1) 
25.5 
(13.7 – 41.7) 
0.20 
Calcineurin inhibitors, tacrolimus [%] 56.7 52.8 72.4 0.007 
 NODAT: New-onset diabetes after transplantation, HCV: hepatitis C 
Supplementary table 3: Clinical characteristics of the solid organ transplantation second replication sample 
Characteristic Total Non-NODAT NODAT p-value 
Sample size 156 111 45  
Age at transplantation (years), median (range) 48 
(22 – 68) 
46 
(22 – 68) 
53 
(28 – 68) 
0.002 
Recipient sex (Males) [%] 60.9 55.9 73.3 0.048 
Living donor [%] 11.5 11.7 11.1 0.915 
Donor age (years), median (range) 43.5 
(10 – 73) 
41 
(10 – 73) 
48 
(13 – 69) 
0.043 
Donor sex (Males) [%] 56.8 63.2 54.8 0.06 
Organ, [%]     0.46 
Kidney 102 [65.4] 75 [67.6] 27 [60.0]  
Liver 37 [23.7] 26 [23.4] 11 [24.4]  
Lung 17 [10.9] 10 [9.0] 7 [15.6]  
Body mass index (kg/m2), median (range)     
Pre-transplant 23.5 
(15.8 – 37.3) 
22.3 
(15.8 – 36.2) 
26.4 
(18.8 – 37.3) 
0.0003 
One year follow-up 26.0 
(16.7 – 43.6) 
25.5 
(16.7 – 43.6) 
27.1 
(19.9 – 42.3) 
0.099 
Calcineurin inhibitors, n [%]     <0.001 
Tacrolimus 54 [34.6] 29 [26.1] 25 [55.6]  
Cyclosporine 102 [65.4] 82 [73.9] 20 [44.4]  
SOT: solid organ transplantation; NODAT: New-onset diabetes after transplantation 
Supplementary table 4: Association between different genotypes and new-onset diabetes after transplantation in 
a discovery sample of solid organ transplant recipients from the Swiss transplant cohort study 
 
Gene,  SNP, function NODAT p-value 
ICAM1, rs5498, missense   
AA (n=229) 1 (Ref.)  
AG (n=341) 0.64 (0.43 - 0.96) 0.03 
GG (n=146) 0.43 (0.24 - 0.78) 0.005 
G Allele dosage 0.65 (0.50 - 0.86) 0.003 
   
CTSZ, rs7341, near Gene-3   
GG (n=251) 1 Ref.  
GT (n=313) 1.02 (0.68 - 1.50) 0.93 
TT (n=129) 0.33 (0.17 - 0.63) 0.001 
T Allele dosage 0.67 (0.51 - 0.88) 0.004 
   
C1QB, rs631090, intron variant   
TT (n=581) 1 (Ref.)  
TC (n=103) 1.55 (0.93 - 2.58) 0.10 
CC (n=8) 25.1 (2.80 - 25.6) 0.004 
C Allele dosage 2.04 (1.32 - 3.13) 0.001 
   
NOD1, rs2907749, near Gene-3   
AA (n=326) 1 (Ref.)  
AG (n=303) 1.27 (0.85 - 1.91) 0.25 
GG (n=63) 3.15 (1.70 - 5.87) 0.0003 
G Allele dosage 1.60 (1.20 - 2.14) 0.001 
   
SP110, rs2114592, intron variant   
CC (n=559) 1 (Ref.)  
CT (n=129) 1.08 (0.67- 1.73) 0.75 
TT (n=7) 11.5 (2.07- 63.3) 0.005 
T Allele dosage 1.42 (0.94 - 2.12) 0.09 
   
TLR10, rs11096956, cds-synon   
GG (n=365) 1 (Ref.)  
GT (270) 1.73 (1.17 - 2.56) 0.006 
TT (n=61) 2.13 (1.13 - 4.04) 0.02 
T Allele dosage 1.52 (1.15 - 2.02) 0.003 
   
TNF, rs3093662, intron variant   
AA (n=585) 1 (Ref.)  
AG (n=102) 1.89 (1.15 - 3.10) 0.01 
GG (n=5) 3.09 (0.48 - 20.0) 0.24 
G Allele dosage 1.86 (1.19 - 2.91) 0.006 
   
P2RX7, rs2393799, near Gene-5   
CC (n=411) 1 (Ref.)  
CT (n=239) 1.48 (0.99 - 2.22) 0.06 
TT (n=42) 2.38 (1.14 - 4.98) 0.02 
T Allele dosage 1.52 (1.12 - 2.05) 0.007 
   
TLR4, rs10759932, near Gene-5   
TT (n=515) 1 (Ref.)  
TC (n=170) 0.53 (0.32 - 0.85) 0.01 
CC (n=8) 0.38 (0.04 - 3.21) 0.37 
C Allele dosage 0.54 (0.34 - 0.85) 0.007 
   
rs6572335, intergenic   
AA (n=172) 1 (Ref.)  
AG (n=362) 1.30 (0.80 - 2.11) 0.28 
GG (n=161) 2.10 (1.23 - 3.59) 0.006 
G Allele dosage 1.46 (1.12 - 1.91) 0.005 
NODAT, new-onset diabetes after transplantation. Results are expressed as odds ratio and (95% 
confidence interval). Statistical analysis by logistic regression adjusting for age of recipient at 
transplantation, sex of the recipient, baseline body mass index (continuous variable), type of 
calcineurin inhibitor (no calcineurin inhibitor / tacrolimus / cyclosporine) and hepatitis C virus 
status (positive / negative). 
Supplementary table 5a: Association between NOD1 rs2907749A>G single nucleotide polymorphism and new-
onset diabetes after transplantation in the Swiss transplant cohort study (STCS) replication sample and the 
combined sample 
AA AG GG G allele dosage 
STCS replication sample 
Sample size 250 176 38 
Odds ratio (95% CI) 1 (ref.) 1.15 (0.69 - 1.92) 2.31 (1.06 - 5.00) 1.39 (0.97 - 1.98) 
P-corrected value* 1.0 0.30 0.70 
Combined STCS samples 
Sample size 576 479 101 
Odds ratio (95% CI) 1 (ref.) 1.19 (0.87 - 1.63) 2.77 (1.72 - 4.44) 1.49 (1.20 - 1.86) 
P-value 0.27 0.00003 0.0004 
CI: confidence interval 
Statistical analysis by logistic regression adjusting for age of recipient at transplantation (continuous variable), sex 
of the recipient, baseline BMI (continuous variable), and type of calcineurin inhibitor (no calcineurin inhibitor / 
tacrolimus / cyclosporine).  
*P- values were corrected using Bonferroni correction for multiple testing (corrected P-value = original p-value x
10)
Supplementary table 5b: Association between NOD1 rs2907749 A>G single nucleotide polymorphism and lipid 
markers in the combined Swiss transplant cohort study sample 
 
 AA AG GG G allele dosage 
Sample size 538 427 86  
New-onset hyperlipidemia  1 (ref.) 1.51 (1.12-2.03) 1.33 (0.79-2.25) 1.29 (1.04-1.60) 
P-value  0.006 0.29 0.02 
Differences (mmol/L)     
Total cholesterol Ref. -0.13 (-0.47; 0.22) 0.98 (0.38-1.59) 0.23 (-0.02; 0.49) 
P-value  0.47 0.002 0.07 
LDL-cholesterol Ref. 0.00 (-0.10; 0.10) -0.02 (-0.20; 0.16) -0.01 (-0.08; 0.07) 
P-value  0.99 0.79 0.85 
HDL-cholesterol Ref. -0.04 (-0.08; -0.003) -0.12 (-0.19; -0.05) -0.05 (-0.08; -0.02) 
P-value  0.02 0.001 0.001 
Results are expressed as odds ratio and (95% confidence interval) for new-onset hyperlipidemia and for difference 
relative to the AA genotype. Statistical analysis performed using logistic regression for new-onset hyperlipidemia 
and for differences in lipid levels, adjusted for age of recipient at transplantation (continuous variable), sex of the 
recipient, baseline BMI (continuous variable) and intake of hypolipidemic drugs (positive / negative coding) 
 
Supplementary table 6: Association between SP110 rs2114592 C>T genotypes and lipid complications in the 
combined Swiss transplant cohort study sample 
 
 CC CT TT T allele dosage 
Sample size 840 219 12  
New-onset hyperlipidemia  1 (ref.) 1.03 (0.73; 1.46) 3.41 (1.06; 11.0) 1.18 (0.87; 1.61) 
P-value  0.85 0.04 0.28 
Differences (mmol/L)     
Total cholesterol Ref. 0.01 (-0.39; 0.42) 1.31 (-0.06; 2.67) 0.17 (-0.19; 0.53) 
P-value  0.94 0.06 0.35 
LDL-cholesterol Ref. 0.08 (-0.04; 0.20) 0.05 (-0.36; 0.45) 0.06 (-0.04; 0.17) 
P-value  0.20 0.82 0.23 
HDL-cholesterol Ref. 0.02 (-0.04; 0.04) -0.07(-0.19; 0.10) 0.00 (0.03; 0.02) 
P-value  0.41 0.19 0.40 
Results are expressed as odds ratio and (95% confidence interval) for new-onset hyperlipidemia and for difference 
relative to the CC genotype. Statistical analysis performed using logistic regression for new-onset hyperlipidemia and 
for differences in lipid levels, adjusted for age of recipient at transplantation (continuous variable), sex of the 
recipient, baseline BMI (continuous variable) and intake of hypolipidemic drugs (positive/negative coding). 
 
  
Supplementary table 7: Associations between SP110 rs2114592 single nucleotide polymorphism and different 
metabolic parameters in the population-based samples 
Phenotype Sample size Beta (95% CI) P-value 
Body mass index 
CoLaus 5’409 0.001 (-0.077 – 0.079) 0.98 
GIANT  250’596 0.0003 (-0.0114 – 0.0120) 0.96 
Waist/hip ratio 
   CoLaus 5’406 0.014 (-0.053 – 0.081)  0.68 
GIANT 156’804 0.009 (-0.004 – 0.022) 0.16 
Glucose 
CoLaus 5’400 -0.029 (-0.098 – 0.040) 0.41 
MAGIC 46’186 0.006 (-0.007 – 0.019) 0.35 
2 hours glucose 
   MAGIC 15’234 -0.067 (-0.131 – -0.003) 0.04 
HOMA-B 
MAGIC 46’186 -0.001 (-0.017 – 0.015) 0.90 
HOMA-IR 
   MAGIC 46’186 0.007 (-0.007 – 0.021) 0.34 
Total cholesterol 
   CoLaus 5’433 0.050 (-0.015 – 0.115) 0.13 
GWAS 100’176 -0.002 (-0.009 – 0.005) 0.58 
HDL-cholestererol 
CoLaus 5’433 -0.005 (-0.027 – 0.017) 0.66 
GWAS 99’892 -0.003 (-0.010 – 0.004) 0.38 
LDL-cholesterol 
   CoLaus 5’358 0.063 (0.006 – 0.120) 0.03 
GWAS 95’446 0.002 (-0.006 – 0.010) 0.64 
Triglycerides 
CoLaus 5’433 -0.014 (-0.085 – 0.057) 0.70 
GWAS 96’590 -0.002 (-0.007 – 0.003) 0.46 
HOMA-IR: surrogate estimates of insulin resistance, HOMA-B: surrogate estimates of beta-cell function, GWAS: 
GWAS for total cholesterol, HDL-C, LDL-C, and triglycerides. Additionally, SP110 rs2114592 was not associated with 
type 2 diabetes in 116’059 individuals from the UK biobank, and no recessive effect was detected (data not 
shown). No significant increase in the prevalence of type 2 diabetes was found in the rs2114592 TT carriers when 
compared to the other genotypes (5.25% versus 5.27%, respectively, covariate adjusted P=0.87). SP110 rs2114592 
was also not associated with type 2 diabetes in the DIAGRAM consortium, a meta-analysis of case-control samples 
with type 2 diabetes (data not shown).  
 
 
Supplementary table 8: Functional tagging single nucleotide polymorphisms (SNP) of SP110 gene 
Gene rs_number Allele Position MAF HWE (p-value) 
SP110 rs3948463 G>A 230172144 9 0.06 
 rs3948464 C>T 230185999 13 0.48 
 rs1135791 T>C 230177560 50 0.14 
 rs7580900 T>C 230216669 46 0.27 
 rs10210254 G>A 230167656 29 0.35 
 rs722555 A>G 230168800 40 0.25 
 rs9784019 A>G 230170859 11 0.89 
 rs28445040 C>T 230245867 18 0.66 
Functional tagging SNPs selected using HapMap Genome Browser by limiting the search to SNPs with a MAF>5% in 
the Caucasian population and r2 cutoff of 0.8. By further limiting the selection to SNPs within the coding region, 5-
UTR and 3’UTR, eight SP110 tagging SNPs were selected and analyzed (see above) 
MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium 
 
 
 
 
 
  
Supplementary table 9: Diagnosis of new-onset diabetes after transplantation (NODAT, transplant population) in 
patients with SP110 rs2114592-TT versus CT/CC genotype groups 
Groups TT CT/CC 
Discovery STCS cohort 5 over 7 (71.4%) 147 over 688 (21.4%) 
First STCS replication sample 5 over 8 (62.5%) 85 over 481 (17.7%) 
Second replication sample 2 over 2 (100%) 26 over 154 (16.9%) 
Combined transplantation sample 12 over 17 (70.6%)& 258 over 1323 (19.5%) 
NODAT: New-onset diabetes after transplantation.  
Results are expressed as number of patients with NODAT or diabetes among all subjects with specific genotypes, 
[%]  
& 17 patients have the rs2114592-TT genotype, among them 12 patients (70.6%) are diagnosed with NODAT  
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